These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19687404)

  • 1. Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.
    Cavalheiro BG; Junqueira CR; Brandão LG
    Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):812-7. PubMed ID: 19687404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of membrane type 1 matrix metalloproteinase in medullary thyroid carcinoma: prognostic implications.
    Cavalheiro BG; Junqueira CR; Brandão LG
    Head Neck; 2010 Jan; 32(1):58-67. PubMed ID: 19536854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
    Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma.
    Määttä M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
    Acta Obstet Gynecol Scand; 2010 Mar; 89(3):380-4. PubMed ID: 20109015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications.
    Cavalheiro BG; Junqueira CR; Brandão LG
    Thyroid; 2008 Aug; 18(8):865-71. PubMed ID: 18651826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
    Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
    Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
    Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
    Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
    Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
    Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
    Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma.
    de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS
    Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
    Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
    Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
    Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
    Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study.
    Xiao M; Zhou NX; Huang ZQ; Lu YL; Chen LH; Wang DJ; Chang WL
    Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):599-602. PubMed ID: 15567754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis.
    de Vicente JC; Lequerica-Fernández P; Santamaría J; Fresno MF
    J Oral Pathol Med; 2007 Aug; 36(7):415-24. PubMed ID: 17617835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
    Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
    Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
    Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma.
    Xu K; Hou S; Du Z
    Chin Med J (Engl); 2002 May; 115(5):743-5. PubMed ID: 12133547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.